EvRest

EvRest is a preclinical-stage biotechnology company specializing in the development of engineered extracellular vesicles (EVs) for therapeutic applications. The company's platform focuses on the precise loading of therapeutic payloads, such as proteins and nucleic acids, into EVs and the engineering of their surfaces for targeted delivery to specific tissues. By leveraging the natural biocompatibility and communication properties of exosomes, EvRest aims to create a new class of medicines that can overcome traditional delivery challenges in oncology and inflammatory diseases. Founded by Dr. Robert Blelloch and backed by The Column Group, the company is advancing a modular pipeline of EV-based candidates designed to provide highly selective and potent therapeutic effects.